Accessibility Menu
Arrow-Thin-Down
S&P 500
6,791.69
+0.8%
+53.25
Arrow-Thin-Down
DJI
47,207.12
+1.0%
+472.51
Arrow-Thin-Down
NASDAQ
23,204.87
+1.1%
+263.07
Arrow-Thin-Down
Bitcoin
$111,292.00
+0.1%
+$61.08
Arrow-Thin-Down
AAPL
$262.83
+1.3%
+$3.25
Arrow-Thin-Down
AMZN
$224.21
+1.4%
+$3.12
Arrow-Thin-Down
GOOG
$260.51
+2.7%
+$6.78
Arrow-Thin-Down
META
$738.36
+0.6%
+$4.36
Arrow-Thin-Down
MSFT
$523.61
+0.6%
+$3.05
Arrow-Thin-Down
NVDA
$186.26
+2.3%
+$4.10
Arrow-Thin-Down
TSLA
$433.72
-3.4%
-$15.26
Daily Stock GainersDaily Stock LosersMost Active Stocks

Summit Therapeutics: A Risky Bet in the Biotech Arena?

By Motley Fool YouTube – Oct 24, 2025 at 7:00PM

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet?

Explore the exciting world of Summit Therapeutics (SMMT +2.83%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Sep. 17, 2025. The video was published on Oct. 17, 2025.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services